# US 2026/0242782 A1 · Crispr/cas-based base editing composition for restoring dystrophin function

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242782 A1
- Document ID: US20260242782A1
- Status: Published application
- Kind: A1
- Application number: 19/663,101
- Filed: 2026-04-29
- Published: 2026-08-20
- Earliest claimed: 2019-04-12
- Assignees: Duke University
- Applicants: Duke University
- Inventors: Charles A. Gersbach; Veronica Gough
- Web page: https://patentgrep.com/patent/US20260242782A1

## CPC

- C12N 15/111: {General methods applicable to biologically active non-coding nucleic acids}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- C07K 14/4708: {Duchenne dystrophy}
- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 9/78: acting on carbon to nitrogen bonds other than peptide bonds (3.5)
- C12N 15/63: Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12Y 305/04005: Cytidine deaminase (3.5.4.5)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- C12N 2740/16043: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Y: ENZYMES

## Abstract

Disclosed herein are CRISPR/Cas-based base editing compositions and methods for treating Duchenne Muscular Dystrophy by restoring dystrophin function.

## Claims

### Claim 1

A CRISPR/Cas-based base editing system for altering an RNA splice site encoded in the genomic DNA of a subject, the CRISPR/Cas-based base editing system comprising a fusion protein and at least one guide RNA (gRNA), wherein the fusion protein comprises a Cas protein and a base-editing domain.

### Claim 2 (depends on 1)

The CRISPR/Cas-based base editing system of claim 1, wherein altering the RNA splice site encoded in the genomic DNA results in exclusion or inclusion of at least one exon sequence in an RNA transcript.

### Claim 3

A CRISPR/Cas-based base editing system for restoring dystrophin function in a subject, the CRISPR/Cas-based base editing system comprising a fusion protein and at least one guide RNA (gRNA), wherein the fusion protein comprises a Cas protein and a base-editing domain.

### Claim 4 (depends on 3)

The CRISPR/Cas-based base editing system of claim 3, wherein the subject has a mutated dystrophin gene, and wherein the at least one guide RNA (gRNA) targets an RNA splice site in the mutated dystrophin gene of the subject.

### Claim 5 (depends on 4)

The CRISPR/Cas-based base editing system of claim 4, wherein administration of the CRISPR/Cas-based base editing system to the subject results in at least one exon sequence being excluded or included in an RNA transcript of the dystrophin gene of the subject and the reading frame of dystrophin gene in the subject being restored.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The CRISPR/Cas-based base editing system of any one of claims 1-5, wherein the at least one guide RNA (gRNA) binds and targets a polynucleotide sequence corresponding to SEQ ID NO: 1.

### Claim 7 (depends on 6)

The CRISPR/Cas-based base editing system of claim 6, wherein the at least one gRNA binds and targets a polynucleotide sequence corresponding to:
a) a fragment of SEQ ID NO: 1;
b) a complement of SEQ ID NO: 1, or fragment thereof;
c) a nucleic acid that is substantially identical to SEQ ID NO: 1, or complement thereof; or
d) a nucleic acid that hybridizes under stringent conditions to SEQ ID NO: 1, complement thereof, or a sequence substantially identical thereto.

### Claim 8 (depends on 6)

The CRISPR/Cas-based base editing system of claim 6, wherein the at least one gRNA comprises a polynucleotide sequence corresponding to SEQ ID NO: 1, or variant thereof.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The CRISPR/Cas-based base editing system any one of claims 1-8, wherein the Cas protein comprises a Cas9, and wherein the Cas9 comprises at least one amino acid mutation which eliminates the nuclease activity of Cas9.

### Claim 10 (depends on 9)

The CRISPR/Cas-based base editing system of claim 9, wherein the at least one amino acid mutation is at least one of D10A, H840A, or a combination thereof, in the amino acid sequence corresponding to SEQ ID NO: 2 or 3.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The CRISPR/Cas-based base editing system of any one of claims 1-10, wherein the Cas protein is a Streptococcus pyogenes Cas9 protein or a Staphylococcus aureus Cas9 protein.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The CRISPR/Cas-based base editing system of any one of claims 1-11, wherein the Cas protein comprises an amino acid sequence of SEQ ID NO: 4 or 5.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The CRISPR/Cas-based base editing system of any one of claims 1-12, wherein the base-editing domain comprises (i) a cytidine deaminase domain and (ii) at least one uracil glycosylase inhibitor (UGI) domain.

### Claim 14 (depends on 13)

The CRISPR/Cas-based base editing system of claim 13, wherein the cytidine deaminase domain comprises an apolipoprotein B mRNA-editing enzyme, catalytic polypeptide-like (APOBEC) deaminase.

### Claim 15 (depends on 13, 14)

The CRISPR/Cas-based base editing system of claim 13 or 14, wherein the cytidine deaminase domain comprises an APOBEC 1 deaminase.

### Claim 16 (depends on 13, 14, 15)

The CRISPR/Cas-based base editing system of any one of claims 13-15, wherein the cytidine deaminase domain comprises a rat APOBEC 1 deaminase.

### Claim 17 (depends on 13, 14, 15, 16)

The CRISPR/Cas-based base editing system of any one of claims 13-16, wherein the at least one UGI domain comprises a domain capable of inhibiting UDG activity.

### Claim 18 (depends on 17)

The CRISPR/Cas-based base editing system of claim 17, wherein the at least one UGI domain comprises the amino acid sequence of SEQ ID NO: 20 or an amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO: 6 or SEQ ID NO: 18.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The CRISPR/Cas-based base editing system of any one of claims 1-18, wherein the base-editing domain comprises one UGI domain or two UGI domains.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The CRISPR/Cas-based base editing system of any one of claims 1-19, wherein the fusion protein comprises the structure: NH2-[cytidine deaminase domain]-[Cas protein]-[UGI domain]-COOH, and wherein each instance of “-” comprises an optional linker.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The CRISPR/Cas-based base editing system of any one of claims 1-20, wherein the fusion protein comprises the structure: NH2-[cytidine deaminase domain]-[Cas protein]-[UGI domain]-[UGI domain]-COOH, and wherein each instance of “-” comprises an optional linker.

### Claim 22 (depends on 21)

The CRISPR/Cas-based base editing system of claim 21, wherein the fusion protein further comprises a nuclear localization sequence (NLS).

### Claim 23 (depends on 22)

The CRISPR/Cas-based base editing system of claim 22, wherein the fusion protein comprises the structure: NH2-[cytidine deaminase domain]-[Cas9 protein]-[UGI domain]-[NLS]-COOH, and wherein each instance of “-” comprises an optional linker.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The CRISPR/Cas-based base editing system of any one of claims 1-23, wherein the fusion protein comprises an amino acid sequence encoded by a polynucleotide corresponding to SEQ ID NO:7 or SEQ ID NO: 8.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

An isolated polynucleotide encoding the CRISPR/Cas-based base editing system of any one of claims 1-24.

### Claim 26 (depends on 25)

The isolated polynucleotide of claim 25, wherein the polynucleotide comprises a first polynucleotide encoding the fusion protein and a second polynucleotide encoding the gRNA.

### Claim 27 (depends on 25, 26)

A vector comprising the isolated polynucleotide of claim 25 or 26.

### Claim 28 (depends on 27)

The vector of claim 27, wherein the vector comprises a heterologous promoter driving expression of the isolated polynucleotide.

### Claim 29 (depends on 25, 26, 27, 28)

A cell comprising the isolated polynucleotide of claim 25 or 26 or the vector of claim 27 or 28.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A composition for restoring dystrophin function in a cell having a mutant dystrophin gene, the composition comprising the CRISPR/Cas-based base editing system of any one of claims 1-24.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

A kit comprising the CRISPR/Cas-based base editing system of any one of claims 1-24, the isolated polynucleotide of claim 25 or 26, the vector of claim 27 or 28, the cell of claim 29, or the composition of claim 30.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

A method for restoring dystrophin function in a cell or a subject having a mutant dystrophin gene, the method comprising contacting the cell or the subject with the CRISPR/Cas-based base editing system of any one of claims 1-24.

### Claim 33 (depends on 32)

The method of claim 32, wherein an “AG” splice acceptor in exon 45 of the mutant dystrophin gene is converted to an “AA” sequence and the dystrophin function is restored by exon 45 skipping.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein the subject is suffering from Duchenne Muscular Dystrophy.
